JAMA Network Open published results of the prespecified secondary analysis of data from the PANOVA-3 trial of Novocure’s TTFields therapy concomitant with gemcitabine and nab-pac in patients with unresectable, locally advanced pancreatic adenocarcinoma: https://t.co/hMH8CUy6R8
Novocure has received a Not Approvable Letter from the U.S. FDA in response to its Premarket Approval (PMA) application for its treatment for adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. Read more: https://t.co/jEwLhY6Ypr
Novocure announced its clinical trial agreement with Verastem Oncology to evaluate TTFields therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, in locally advanced pancreatic cancer: https://t.co/L31VZAdSjv
Novocure announced today that its treatment for adult patients diagnosed with unresectable locally advanced pancreatic cancer was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for concomitant use with gemcitabine and nab-paclitaxel: https://t.co/7gWkXIBI9E
Novocure will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Read more in our press release: https://t.co/fgfOYCG4T4
Novocure will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Read more in our press release: https://t.co/FqZnQSRXhm
Novocure announced today that its treatment has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel in accordance with guideline recommendations. https://t.co/QjeaqXQfc1
Novocure announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy. Read more in our press release: https://t.co/42QnnbK1lD
Today Novocure announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its treatment for non-small cell lung cancer through the country’s National Health Insurance coverage.
Read more in our press release: https://t.co/YEU1UsKDMn
Novocure today reported financial results for the quarter and full year ended December 31, 2025.
Read more in our press release: https://t.co/05fW4pfEFW
We are thrilled to see the news of our Optune Pax approval featured on the Nasdaq tower this morning.
Read more about the approval in our latest press release: https://t.co/bo8nPXIqm9
Thank you to the team at Nasdaq!
Yesterday, the U.S. Food and Drug Administration (FDA) approved Novocure’s treatment for adult patients with locally advanced pancreatic cancer concurrently with gemcitabine and nab-paclitaxel.
Read more in our press release: https://t.co/bo8nPXIqm9
The U.S. Food and Drug Administration (FDA) has approved Novocure’s treatment for adult patients with locally advanced pancreatic cancer concurrently with gemcitabine and nab-paclitaxel.
https://t.co/bo8nPXHSwB